ºÚÁÏÍø

Skip to main content
Tal Kafri, MD, PhD – Microbiology and Immunology

ºÚÁÏÍø


Tal Kafri, MD, PhD

Professor

Tal Kafri, MD, PhD

Contact Information

Address

Office:
104 Manning Drive
5019 Thurston-Bowles Building
Chapel Hill, NC 27599

Resources

Tal Kafri, MD, PhD

Professor

Areas of Interest

Lentiviral vector-based Gene therapy

About

Lentiviral vectors efficiently ferry large genetic cargos to dividing and non-dividing cells in vitro and in vivo. ÌýIntegration of the vector genome into host cell chromatin is the hallmark of lentiviral vectors, which bestows vector genome persistency in proliferating cells and thus renders lentiviral vectors ideal for human gene therapy applications. This notion has been strongly supported by recent successes in correcting human genetic diseases, and curing patients with hematologic and solid tumors. ÌýThe need to utilize the capabilities offered by lentiviral vectors and yet to avoid the risks of insertional mutagenesis was the initial drive for the development of integration deficient lentiviral vector (IDLV) systems. In addition the rapid clearance of episomal-IDLV genomes in proliferating cells renders IDLV’s highly suitable for recently emerging research and clinical applications premised on transient transgene expression, including immunotherapy, gene vaccination, and genome editing (using the CRISPR and the zinc-finger nucleases technologies). Our laboratory has been focused on overcoming major impediments inherent to episomal viral vectors. These include: epigenetic silencing of episomal vectors, illegitimate integrase-independent integration, and the lack of IDLV stable packaging cell lines (see selected publications).

In addition we are interested in developing precision gene therapy approach, to this end our laboratory is focused on studying the effects of the host genetic background on the efficacy and safety of lentiviralÌývector gene delivery (see selected publication.

Finally, we recently initiated a new NIH funded study aimed at characterizing the effects of the circadian rhythm on in vivo and in vitro gene delivery by viral vectors.

Publications

  • Hu et.al.ÌýGene Ther. 2018 Oct;25(7):454-472
  • Suwanmanee et.al.ÌýMol Ther Methods Clin Dev. 2017 Jun 16;5:83-92
  • Hu et.alÌý.ÌýMol Ther Methods Clin Dev. 2015;2:15025.
  • Cockrell et.al.ÌýRetrovirology. 2011 Jun 24;8:51. doi: 10.1186/1742-4690-8-51
  • Kantor et.al.ÌýMol Ther. 2011 Mar;19(3):547-56.
  • Kantor et.al.ÌýProc Natl Acad Sci U S A. 2009 Nov 3;106(44):18786-91

  • MD PhD

    The Hebrew University Jerusalem Israel